# Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

> **NCT00769145** · PHASE1 · COMPLETED · sponsor: **University of Miami** · enrollment: 5 (actual)

## Conditions studied

- Corneal Neovascularization

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00769145
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-08
- **Final completion:** 2012-03
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00769145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00769145, "Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00769145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*